Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 275-063-2 | CAS number: 70955-74-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
There were no signs of acute toxicity via the oral, dermal or inhalation routes.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: guideline GLP study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- GLP compliance:
- yes
- Test type:
- up-and-down procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- The undiluted test substance was administered to the stomach using a stainless steel ball-tipped gavage needle attached to an appropriate syringe. Following administration, each animal was returned to its designated cage. Feed was replaced approximately 3-4 hours after dosing.
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- An initial limit dose of 2,000 mg/kg was administered to one healthy female rat by oral gavage. Due to the absence of mortality in this animal, four additional females received the same dose level, sequentially. Since these animals survived, no additional animals were tested. Females were selected for the test because they are frequently more sensitive to the toxicity of test compounds than males. All animals were observed for mortality, signs of gross toxicity, and behavioral changes at least once daily for 14 days after dosing. Body weights were recorded prior to administration (initial) and again on Days 7 and 14 (terminal) following dosing (see Section 9). Necropsies were performed on all animals at terminal sacrifice.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no mortality at limit dose
- Mortality:
- None
- Clinical signs:
- No signs of gross toxicity, adverse pharmacologic effects, or abnormal behaviour.
- Body weight:
- All animals gained weight during the study.
- Gross pathology:
- No gross abnormalities were noted for any of the animals when necropsied at the conclusion of the 14-day observation period.
- Interpretation of results:
- practically nontoxic
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study, the acute oral LD50 of triisotridecyl phosphite is greater than 2,000 milligrams per kilogram of body weight in female rats. In accordance with the provisions of Regulation (EC) Number 1272/2008 amended by Commission Regulation (EU) Number 286/2011 of 10 March 2011 (ATP002) on the Classification, Labeling, and Packaging of Substances and Mixtures, classification is not required based on the results of this study.
- Executive summary:
Under the conditions of this study, the acute oral LD50 of triisotridecyl phosphite is greater than 2,000 milligrams per kilogram of body weight in female rats. In accordance with the provisions of Regulation (EC) Number 1272/2008 amended by Commission Regulation (EU) Number 286/2011 of 10 March 2011 (ATP002) on the Classification, Labeling, and Packaging of Substances and Mixtures, classification is not required based on the results of this study.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: No further information available.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- not specified
- Principles of method if other than guideline:
- Other (1980).
- GLP compliance:
- yes
- Test type:
- other: Needed for data submission
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: Sherman/Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Housing: The animals were housed and maintained in compliance with the Animal Welfare Act (Pub. L-94-279) 9 CFR, Part 3.
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: plexiglass exposure chamber
- Exposure chamber volume: 260-L
- Source and rate of air: rate of flow through the chamber was 20 L/min
- System of generating particulates/aerosols: The material was administered as an aerosol, which was generated by a six-jet Collision nebulizer (BGI Incorporated, Waltham, MA). The air was passed through a desicant prior to being passed through the test material.
- Method of particle size determination:
- Temperature: 72o F
TEST ATMOSPHERE
- Brief description of analytical method used: The average concentration of the aerosol over the one-hour exposure period was calculated to be 12.6 mg/L by differential weighing of the flask from which the aerosol was generated. The particle size (mass median diameter) of the aerosol of the test material was determined, to assure that the animals received a respirable dose, using an Andersen Sampler cascade impactor. The sampler was run for 5 minutes midway through the exposure. During sampling, air from the breathing zone of the animals was drawn through the cascade impactor at the rate of 1 ft3/min. The amount of aerosol impacting on each plate of the Andersen Sampler was determined by differential weighing. From these values the mass median diameter of the aerosol was calculated to be 0.48 microns and the concentration was calculated to be 0.10 mg/L. - Analytical verification of test atmosphere concentrations:
- not specified
- Duration of exposure:
- 1 h
- Concentrations:
- No further information available.
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 21 days
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 12.6 mg/L air
- Mortality:
- No animals died during the experiment.
- Clinical signs:
- other: No adverse effects were observed during the one-hour exposure period. No untoward signs and symptoms were observed during the 21-day post-exposure observation period.
- Gross pathology:
- Gross pathological examination revealed no remarkable findings.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- There were no signs of acute inhalation toxicity based on exposure to an aerosol (above vapour saturation point).
- Executive summary:
LC50 (aerosol) was >12.6 mg/L. The substance is not acutely toxic via the inhalation route and not classifiable.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 12 600 mg/m³
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Comparable to OECD 402, except this limit test used 3 animals/sex rather than 5/sex as recommended by the OECD guideline.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Principles of method if other than guideline:
- Other (1980). The method employed in the testing, evaluation, and the scoring of the results was similar to the methods described in Section 1500.40 of the U.S. Federal Hazardous Substances Act Regulations, 16 CFF, pg. 123.
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 2.0 and 3.0 kg
- Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: dorsal
- Type of wrap if used: These treated areas were covered with large gauze patches and an impervious material was wrapped around the trunk of each animal.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): excess material was removed.
- Time after start of exposure: 24 hours - Duration of exposure:
- 24 hours
- Doses:
- 5.0 g/kg body weight
- No. of animals per sex per dose:
- 3
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 21 days
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Mortality:
- No animals died during the experiment.
- Clinical signs:
- No signs of toxicity, except for substantial skin irritation lasting over several days.
- Gross pathology:
- Gross pathological examination revealed no remarkable findings.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- No signs of dermal toxicity at the limit dose of 5 g/kg.
- Executive summary:
No acutely toxic via the dermal route at limit dose of 5 g/kg. Not classified as acutely toxic.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
Additional information
There are no indications of acute toxicity via the oral route for TiTDP (Lowe 2014). In addition, there was no acute toxicity via the oral, dermal or inhalation routes for close analogue - triisodecyl phosphite (TDP).
Use of TDP dermal acute toxicity data as read-across to TiTDP appears appropriate based on the similar acute toxicity of these alkyl phosphites. From the enhanced read-across justification (Section 13), it is also noted that the corresponding alkyl alcohols (hydrolysis products) for these phosphites also have low dermal toxicity.
Given the extremely low vapour pressure of TiTDP, it is not feasible to test via the inhalation route. Read-across data from TDP for the acute inhalation endpoint has been used in the CSR, though inhalation is not considered to be a major exposure pathway.
Justification for selection of acute toxicity – oral endpoint
No acute oral effects observed at the limit dose.
Justification for selection of acute toxicity – inhalation endpoint
No effects observed in an acute aerosol inhalation toxicty study done on close analog, triisodecyl phosphite. Substance is not volatile and inhalation exposure is not expected to occur so a waiver has been submitted for this endpoint.
Justification for selection of acute toxicity – dermal endpoint
No effects observed in an acute dermal toxicity study done on close analog, triisodecyl phosphite. Substance is classified as a skin sensitiser so exposure to skin is already being controlled. A waiver has been submitted for this endpoint.
Justification for classification or non-classification
The following information is taken into account for any hazard / risk assessment:
There were no signs of acute toxicity via the oral and read-across data from TDP suggests no acute toxicity via the dermal or inhalation routes.
The results justify non classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.